Oppenheimer & Co. Inc. Raises Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Oppenheimer & Co. Inc. increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 6.3% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,225 shares of the medical equipment provider’s stock after acquiring an additional 1,250 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Hologic were worth $1,530,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. General Partner Inc. acquired a new stake in Hologic during the 4th quarter worth $26,000. Groupama Asset Managment boosted its stake in Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after purchasing an additional 261 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Finally, Covestor Ltd boosted its stake in Hologic by 23.8% during the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after purchasing an additional 133 shares during the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Trading Down 0.2 %

NASDAQ HOLX opened at $63.27 on Tuesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The stock has a market capitalization of $14.20 billion, a P/E ratio of 19.96, a PEG ratio of 2.14 and a beta of 0.97. The firm’s 50-day moving average is $68.98 and its two-hundred day moving average is $75.78. Hologic, Inc. has a 12 month low of $62.69 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. JPMorgan Chase & Co. boosted their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Stephens reissued an “overweight” rating and set a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Finally, Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $85.77.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.